Yu-Jet Co., Ltd.
Update：2026/04/17
Industries
Main Industry
Health Care
Main Product/Service
Drug R&D: In addition to new drug development, it integrates medical devices and a clinical decision support system (CDSS), forming a comprehensive treatment approach centered on “drug × system × data.”
In-licensed product portfolio: The current product pipeline covers epilepsy, Fabry’s disease, and cytomegalovirus (CMV) infection, with multiple dosage forms including buccal solutions and injections.
Precision medicine systems: Clinical decision support systems, EEG and full-body stress sensing devices.
In-licensed product portfolio: The current product pipeline covers epilepsy, Fabry’s disease, and cytomegalovirus (CMV) infection, with multiple dosage forms including buccal solutions and injections.
Precision medicine systems: Clinical decision support systems, EEG and full-body stress sensing devices.
Founded Year
2014
Unified Business No.
24756152
Status
Active
Number of Employees
0
Total Paid-in
Capital
177,163,840 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Yu-Jet is a Taiwan-based biotech company focused on developing treatments for rare diseases. It integrates drug formulation development, clinical research, and clinical decision support systems (CDSS), built upon three pillars: drug development, precision medicine, and clinical application. The company targets rare diseases and central nervous system (CNS) disorders, and accelerates the introduction of innovative therapies through strategic partnerships with global pharmaceutical companies. Its CDSS platform combines clinical data, AI algorithms, and medical knowledge bases to support physicians in diagnosis and treatment decisions, improving efficiency and patient safety.
